Navigation Links
Little evidence supports autism treatment options in adolescents
Date:8/27/2012

Vanderbilt University researchers studying interventions for adolescents and young adults with autism are reporting today that there is insufficient evidence to support findings, good or bad, for the therapies currently used.

Although the prevalence of autism is on the rise, much remains to be discovered when it comes to interventions for this population, the researchers concluded.

"Overall, there is very little evidence in all areas of care for adolescents and young adults with autism, and it is urgent that more rigorous studies be developed and conducted," said Melissa McPheeters, Ph.D., M.P.H., director of Vanderbilt's Evidence-Based Practice Center and senior author of the report, a systematic review of therapies published by the Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ).

Zachary Warren, Ph.D., director of the Vanderbilt Kennedy Center's Treatment and Research Institute for Autism Spectrum Disorders, said, "There are growing numbers of adolescents and adults with autism in need of substantial support. Without a stronger evidence base, it is very hard to know which interventions will yield the most meaningful outcomes for individuals with autism and their families."

Key findings:

The researchers systematically screened more than 4,500 studies and reviewed the 32 studies published from January 1980 to December 2011 on therapies for people ages 13 to 30 with autism spectrum disorders. They focused on the outcomes, including harms and adverse effects, of interventions, including medical, behavioral, educational and vocational.

Some evidence revealed that treatments could improve social skills and educational outcomes such as vocabulary or reading, but the studies were generally small and had limited follow-up.

Limited evidence supports the use of medical interventions in adolescents and young adults with autism. The most consistent findings were identified for the effects of antipsychotic medications on reducing problem behaviors that tend to occur with autism, such as irritability and aggression. Harms associated with medications included sedation and weight gain.

Only five articles tested vocational interventions, all of which suggested that certain vocational interventions may be effective for certain individuals, but each study had significant flaws that limited the researchers' confidence in their conclusions. The researchers' findings on vocational interventions will be featured in the Aug. 27 issue of Pediatrics.

As recently as the 1970s, autism was believed to affect just one in 2,000 children, but newly released data from the Centers for Disease Control and Prevention (CDC) estimates that one in 88 children has an autism spectrum disorder. Boys with autism outnumber girls 5-to-1, which estimates that one in 54 boys in the United States have autism.

"With more and more youth with autism leaving high school and entering the adult world, there is urgent need for evidence-based interventions that can improve their quality of life and functioning," said Julie Lounds Taylor, Ph.D., assistant professor of Pediatrics and Special Education and lead author of the report.


'/>"/>

Contact: Jennifer Wetzel
jennifer.wetzel@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Milk Thistle of Little Help Against Hepatitis C: Study
2. Kids Born Even a Little Early Have Lower School Scores: Study
3. New federal disclosure law may have little impact on drugs prescribed
4. Too much vitamin D can be as unhealthy as too little
5. OSHAs Safety Tests Protect Workers at Little Cost: Study
6. A Little More Education, a Little Longer Life?
7. Botox Offers Little Relief for Migraine, Study Finds
8. U.S. Spends Too Little on Public Health Initiatives: Report
9. In children born with severe heart defect, surgical management has little effect on neuro outcomes
10. First evidence from humans on how alcohol may boost risk of cancer
11. No evidence that drug used for preventing life-threatening bleeding in women during labor works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Southland ... line of classic American timber frame barn kits, which can be found on its ... inspired by historic American barn plans, and they highlight the craftsmanship of timber post ...
(Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke survivors ... sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics had ... with hemiplegia due to stroke. , Ekso Bionics has now received clearance from the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated a new ... This is the first time that Coolsculpting is being used for for more than ... to ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
Breaking Medicine Technology: